2021 | Nanologica

Förändring av antal aktier i Nanologica AB

26 February, 2021

Översättning Delar av Nanologicas optionsprogram 2018/21 har lösts in av optionsinnehavarna, vilket medför en ökning av antalet aktier i bolaget med 17 630 till 27 794 480 aktier. Aktiekapitalet ökar som en följd av detta med 7 228,79 SEK till 11 396 509,12 SEK. Vid Nanologicas årsstämma den 31 maj 2018 beslutades om att inrätta ett incitamentsprogram om maximalt 484 883 teckningsoptioner för bolagets anställda. Varje teckningsoption ger rätten att teckna en aktie i bolaget till en teckningskurs

Nanologica Recruits SVP Sales and Senior Advisor for Chromatography

18 February, 2021

Nanologica has recruited Dr. PK Dutta as SVP Sales and Senior Advisor for the business area of chromatography. Dr. PK Dutta will focus on sales growth of Nanologica’s chromatography products primarily in the US. To accelerate sales of chromatography products following the successful upscaling of Nanologica’s silica towards ton scale, Dr. Dutta has been recruited as SVP Sales and Senior Advisor. The position includes leading efforts and strategy for market growth in direct and indirect

Nanologica rekryterar SVP Sales and Senior Advisor för kromatografi

18 February, 2021

Nanologica har rekryterat Dr. PK Dutta till positionen som SVP Sales and Senior Advisor för affärsområdet kromatografi. Dr. PK Dutta kommer att fokusera på försäljningstillväxt av Nanologicas produkter för kromatografi primärt i USA. För att accelerera försäljningen av kromatografiprodukter, efter den lyckade uppskalningen av Nanologicas silikaproduktion till tonskala, har Dr. Dutta rekryterats som SVP Sales and Senior Advisor. Rollen innefattar att sätta strategier för tillväxt, samt leda direkt och indirekt försäljning med fokus på Nordamerika.

Interview in Penserpodden

11 February, 2021

CEO Andreas Bhagwani interviewed in Erik Penser Bank’s podcast Penserpodden. Available on this link and on Spotify.

Job Opening – Process Chemist

10 February, 2021

We are currently looking for a Process Chemist who likes to solve problems and develop optimised ways of working. You will work closely with our manufacturing unit, but it is R&D that is hosting this position. Formulation and chemical modification are key words! Read more about the job and how to apply here: Job advertisement Process Chemist at Nanologica Last application date: Feb 25, 2021.

Nanologica Signs Collaboration Agreement with Zentiva for the use of NLAB Drug Delivery Platforms

27 January, 2021

A collaboration agreement for the use of the NLAB drug delivery platforms has been signed with Zentiva, a pharmaceutical company operating in Europe and beyond. The aim of this collaboration agreement is to simplify the contract process for future product-specific agreements. The agreement gives Zentiva the right to use the NLAB drug delivery platforms for multiple drug development projects. Project specific agreements will be signed separately under this collaboration agreement. ” We first met Zentiva

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.